Stanislas Blein

USPTO Granted Patents = 15 (Patent Applications = 18)

CIPO Patents = 3 (Patent Applications = 8)

EPO Patents = 7 (Patent Applications = 16)

Average Co-Inventor Count = 4.2

ph-index = 7

Forward Citations = 172(Granted Patents)

Location History:

Cernier, CH (2015 - 2022)
La Chaux-de-Fonds, CH (2012 - 2024)

Company Filing History:

7 out of 64

Glenmark Pharmaceuticals S.a.

Years Active: 2012-2025

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12338292 - CD47-CD38 bispecific antibodies (2025-06-24),

2. 12281169 - Antibodies that bind to OX40 and their uses (2025-04-21),

3. 11891454 - Production of T cell retargeting hetero-dimeric immunoglobulins (2024-02-06),

4. 11851502 - Production of T cell retargeting hetero-dimeric immunoglobulins (2023-12-26),

5. 11407839 - Antibodies that bind to OX40 and their uses (2022-08-09),

6. 11267891 - Fc variant antibodies and their uses (2022-03-08),

7. 10640564 - Antibodies that bind to CCR6 and their uses (2020-05-05),

8. 9683053 - Hetero-dimeric immunoglobulins (2017-06-20),

9. 9683052 - Hetero-dimeric immunoglobulins (2017-06-20),

10. 9493563 - Production of T cell retargeting hetero-dimeric immunoglobulins (2016-11-15),

11. 9290576 - Antibodies that bind to TL1A and their uses (2016-03-22),

12. 8975376 - Anti-alpha2 integrin antibodies and their uses (2015-03-10),

13. 8748585 - Antibodies that bind to OX40 and their uses (2014-06-10),

14. 8679492 - Humanized antibodies that bind to CD19 and their uses (2014-03-25),

15. 8236315 - Humanized antibodies specific for von Willebrand factor (2012-08-07),

Title: Stanislas Blein: Innovator in Immunology

Introduction

Stanislas Blein, a notable inventor based in La Chaux-de-Fonds, Switzerland, has made significant contributions to the field of immunology with a total of 13 patents to his name. His innovative work focuses on the development of bispecific antibodies, which are essential in the treatment of various diseases, including cancers.

Latest Patents

Among Stanislas Blein's latest patents are groundbreaking inventions related to bispecific heterodimeric immunoglobulins. His patent on CD47-CD38 bispecific antibodies describes novel immunoglobulins that target both components of the human CD47 and CD38 antigens. This invention holds promise for treating autoimmune and proliferative diseases, particularly hematologic malignancies and solid tumors.

Another noteworthy patent involves antibodies that bind to OX40. This invention details antagonist antibodies or fragments that specifically target human OX40, including detailed amino acid sequences for heavy and light chain variable regions. These innovations are instrumental in advancing therapeutic methodologies in immunotherapy.

Career Highlights

Stanislas Blein has worked with reputable companies in the pharmaceutical industry, including Glenmark Pharmaceuticals and Ichnos Sciences. His experience has enhanced his expertise in developing innovative treatments that address complex medical conditions, demonstrating his commitment to improving patient outcomes through scientific advancements.

Collaborations

Throughout his career, Stanislas Blein has collaborated with talented individuals, including Samuel Hou and Darko Skegro. These collaborations have undoubtedly contributed to the refinement and success of his innovative projects, reflecting the importance of teamwork in the field of scientific research.

Conclusion

In conclusion, Stanislas Blein stands out as a prolific inventor whose work in the development of bispecific antibodies has the potential to transform therapeutic strategies for treating autoimmune diseases and cancers. His dedication to innovation in immunology continues to pave the way for future advancements, making him a significant figure in the landscape of modern medicine.

This text is generated by artificial intelligence and may not be accurate.